UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
ONCOLOGY

APOGEPHA

Established German pharmaceutical company in urology and oncology

APOGEPHA logo

APOGEPHA

OncologyGermany

Established German pharmaceutical company in urology and oncology

Visit Website

About APOGEPHA

Specialist expertise in urological medicine defines APOGEPHA Arzneimittel GmbH, a German pharmaceutical company that develops and markets a dedicated range of drugs addressing the full spectrum of urological conditions. Operating under the positioning of "Your partner in urology," the company brings together therapeutic products and professional resources for a primarily specialist audience of healthcare professionals and industry partners.

The urological drug portfolio covers a broad clinical range, including treatments and information resources for bedwetting in children, bladder weakness, irritable bladder, cystitis, prostatitis, prostate enlargement, urination disorders, bladder cancer, and prostate cancer. This focused therapeutic breadth reflects a commitment to addressing both benign and oncological conditions within the specialty. The company also addresses oncology-related indications including neutropenia, extending its reach beyond urology into supportive cancer care.

APOGEPHA engages actively with the urological medical community, hosting and supporting professional events such as the Dresden Urology Day, a scientific conference featuring lectures, workshops, and discussion with specialist speakers. A dedicated login area for specialist groups further underlines the company's orientation towards medical professionals rather than general consumers.

The company operates internationally, with its website available in both German and English, and maintains commitments to sustainability and innovation as part of its stated corporate values. Careers and partnerships are also highlighted as active areas of development.

Further information is available at apogepha.de/en/.

Areas of Expertise

Drug DevelopmentOncologyUrology

Services & Capabilities

Drug DevelopmentOncologyUrology
Similar Companies

More in Oncology

A

AdoRx Therapeutics

Founded in Edinburgh in 2017, AdoRx Therapeutics is a clinical-stage oncology drug discovery company built around a single well-validated biological insight: high concentrations of adenosine within the tumour microenvironment allow cancer cells to evade immune surveillance. The company designs small-molecule adenosine receptor antagonists intended to disrupt that immune evasion and restore anti-tumour activity. Pipeline and Scientific Platform AdoRx focuses on two mechanistic targets: selective antagonists of the adenosine A2A receptor and dual-blockade compounds targeting both A2A and A2B receptors simultaneously. The dual-blockade approach is designed to address the redundancy that can limit single-target therapies in the adenosine pathway. The leadership team brings more than 60 years of combined drug-discovery experience across biotech and pharma, having collectively contributed to the identification of over 25 clinical candidates. Funding and Partnerships The company was seeded with $10 million in initial funding from Epidarex Capital and Sixth Element Capital, both specialist life-sciences investors. In 2019, AdoRx secured a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson, under which J&J received an exclusive option to research, develop and commercialise novel adenosine antagonists from the AdoRx portfolio. The partnership underscores the scientific and commercial credibility of the company's immuno-oncology platform. Further information is available at adorx.com.

View profile
R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
A

Alacris Theranostics

Alacris Theranostics positions itself as a systems medicine company, delivering integrated next-generation sequencing (NGS) services and bioinformatics solutions designed to translate multi-modal omics data into actionable insights for researchers, pharmaceutical partners and healthcare professionals. Based in Germany, the company's core offering spans the full omics workflow, from NGS data generation through to computational interpretation. Its bioinformatics capability is presented as central to the value proposition, enabling clients to move from raw sequencing output to clinically and scientifically meaningful results without switching vendors or platforms. The company also offers immune repertoire analysis alongside its broader genomics portfolio. A distinctive element of Alacris Theranostics' research and development work is the ModCell digital twin concept, a computational modelling approach aimed at supporting personalised medicine applications. The Alacris-CMTA platform is referenced within this context, reflecting an ambition to connect molecular profiling with precision oncology decision-making. The company's stated mission is to make comprehensive NGS services accessible across the research and pharma sectors, with a declared focus on advancing precision medicine and improving patient outcomes. Its approach emphasises customisation, on the basis that each project and each patient presents distinct challenges that standardised pipelines may not adequately address. Quality management, equality and diversity commitments, and an environmental policy statement are all cited on its public-facing communications, indicating structured internal governance. Further information is available at alacris.de.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy